Resverlogix Corp
TSX:RVX

Watchlist Manager
Resverlogix Corp Logo
Resverlogix Corp
TSX:RVX
Watchlist
Price: 0.135 CAD 8% Market Closed
Market Cap: 38.3m CAD

Net Margin
Resverlogix Corp

0%
Current
0%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-14m
/
Revenue
0

Net Margin Across Competitors

Resverlogix Corp
Glance View

Market Cap
38.3m CAD
Industry
Biotechnology

Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.

RVX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-14m
/
Revenue
0
What is the Net Margin of Resverlogix Corp?

Based on Resverlogix Corp's most recent financial statements, the company has Net Margin of 0%.

Back to Top